SecBot SecBot
PRESS-RELEASE ·Filed Nov 10, 2026

OCGN

Ocugen
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 19h ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

The deal provides modest near-term cash ($6.1M tied to near-term milestones) and validates OCU400's commercial potential outside the U.S. The key catalyst remains Phase 3 topline data in Q1 2027, which will determine the program's viability and broader partnership value.

DirectionNeutral
Confidencehigh
Horizonmonths

OCU400

▲ Bullish Named in this press release
Impact
Phase
Phase 3
Time to market
Potential FDA approval in 2027-2028 if Phase 3 succeeds and BLA submission (targeted Q3 2026 rolling) is accepted.
Next catalyst
None dated

What to watchWatch for the rolling BLA submission in Q3 2026 as a validation event and the Phase 3 topline readout in Q1 2027 as the primary binary catalyst. The stock has strong institutional accumulation and analyst support (9 Buy, mean PT ~$11.43 vs ~$1.43), but remains pre-revenue with high dilution risk from $130M convertible notes. The Phase 1/2 data was encouraging, durability and a gene-agnostic approach differentiate OCU400 from the only approved therapy, Luxturna.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$0.9500
T+0 close · Nov 10, 2026 · via day close
Latest settled
+1.09%
T+1 · $0.9604
Vs SPY
−0.22%
α at T+1
Next horizon
T+5
in 4h
  1. T+0 · Nov 10 $0.9500entry
  2. T+1 · 6d ago +1.09%α −0.22% · $0.9604
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocugen granted Celairis exclusive rights to commercialize OCU400, its investigational gene therapy for retinitis pigmentosa, in Australia, New Zealand, and ASEAN markets. Ocugen receives an upfront fee and potential milestone payments totaling up to $7.1 million, plus royalties and profit share. The deal expands global access for OCU400 ahead of Phase 3 topline data expected in Q1 2027.

Key Financial Metrics

Deal Value
$7.1M

Key Facts

  • Exclusive license agreement for OCU400 in Australia, New Zealand, and ASEAN markets
  • Upfront license fee plus potential development and milestone payments totaling up to $7.1 million, including $6.1 million tied to upfront and OCU400 top-line results
  • High single-digit percentage royalty on net sales and 50% of gross profits from OCU400 net sales in the territory
  • Celairis responsible for regional regulatory submissions, market access, and commercialization
  • OCU400 Phase 3 topline data expected in Q1 2027, followed by planned global regulatory submissions
  • This is Ocugen's third strategic regional partnership for OCU400

Financial Impact

Up to $7.1 million in upfront and milestone payments, plus high single-digit royalty and 50% profit share on net sales in the territory

revenuecash flow

Risk Factors

  • OCU400 has not been approved in any market; regulatory approval is uncertain
  • Milestone payments depend on clinical and regulatory success
  • Financial terms are modest relative to Ocugen's $314M market cap
  • Supply agreement not yet finalized

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3399307

Track record

23 reports on OCGN

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  2. Nov 10, 20266d ago Press Release Neutral 4/10 Viewing Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  3. Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  4. Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
  7. Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  8. Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  9. Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026